Current Assets
Available For Sale Securities Debt Securities Current
Pfizer Available For Sale Securities Debt Securities Current decreased by 10.8% to $8.19B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 41.3%, from $13.95B to $8.19B. Over 5 years (FY 2020 to FY 2025), Available For Sale Securities Debt Securities Current shows relatively stable performance with a -1.1% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ4 2017
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase suggests higher liquidity and a conservative cash management strategy, while a decrease may indicate cash deployment for operations or acquisitions.
Detailed definition
This represents the portion of a company's investment portfolio consisting of debt securities that are expected to be so...
Peer comparison
Common among large-cap pharmaceutical firms maintaining significant cash reserves for R&D and M&A activities.
Metric ID:
current_assets_available_for_sale_securities_debt_securi_87ec82Historical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $14.03B | $22.89B | $22.01B | $17.34B | $25.62B | $20.18B | $18.74B | $16.12B | $24.09B | $26.25B | $4.40B | $8.22B | $4.40B | $6.85B | $10.88B | $13.95B | $9.53B | $10.12B | $9.18B | $8.19B |
| QoQ Change | — | +63.2% | -3.8% | -21.2% | +47.8% | -21.3% | -7.1% | -14.0% | +49.5% | +8.9% | -83.2% | +86.8% | -46.4% | +55.6% | +58.9% | +28.2% | -31.7% | +6.3% | -9.3% | -10.8% |
| YoY Change | — | — | — | — | +82.7% | -11.8% | -14.9% | -7.0% | -6.0% | +30.1% | -76.5% | -49.0% | -81.7% | -73.9% | +147.3% | +69.8% | +116.4% | +47.8% | -15.6% | -41.3% |
Range$4.40B – $26.25B
CAGR-10.7%
Avg YoY Growth+7.3%
Median YoY Growth-9.4%
Current Streak2 quarters decline
Available For Sale Securities Debt Securities Current at Other Companies
Frequently Asked Questions
- What is Pfizer's available for sale securities debt securities current?
- Pfizer (PFE) reported available for sale securities debt securities current of $8.19B in Q1 2026.
- How has Pfizer's available for sale securities debt securities current changed year-over-year?
- Pfizer's available for sale securities debt securities current decreased by 41.3% year-over-year, from $13.95B to $8.19B.
- What is the long-term trend for Pfizer's available for sale securities debt securities current?
- Over 5 years (2020 to 2025), Pfizer's available for sale securities debt securities current has grown at a -1.1% compound annual growth rate (CAGR), from $9.71B to $9.18B.
- What does available for sale securities debt securities current mean?
- Short-term investments in debt securities that the company intends to sell within a year.